APH vs PACB · P/E 40, rev $23.09B vs rev $38.4M
Amphenol Corporation (APH) versus Pacific Biosciences of California (PACB) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported PACB revenue for 2025-09-30 was $38.4M. Net income was -$38.0M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. PACB currently screens at market cap $387.1M.
APH currently screens at market cap $170.77B and trailing P/E 39.9. PACB currently screens at market cap $387.1M.
Not investment advice. Open the APH and PACB stock pages for the full models.
Not investment advice.